NCT07153692 Clinical Efficacy and Mechanism of tDCS for Dysphagia in PD
| NCT ID | NCT07153692 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wang Ping |
| Condition | Parkinson's Disease and Parkinsonism |
| Study Type | INTERVENTIONAL |
| Enrollment | 58 participants |
| Start Date | 2025-07-17 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 58 participants in total. It began in 2025-07-17 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to verify transcranial direct current stimulation(tDCS) efficacy for Parkinson's disease (PD)-related dysphagia and its mechanism. Subjects are randomly split into two groups: control (sham tDCS + conventional dysphagia treatment) and experimental (real tDCS + conventional treatment). Assessments will be conducted at baseline, after the completion of intervention, and at the 3-month follow-up. Swallowing function will be evaluated via gold-standard videofluoroscopic swallowing study (VFSS) and scales. Resting-state functional magnetic resonance imaging (rs-fMRI) or functional near-infrared spectroscopy (fNIRS) will be measures for tracking changes in abnormal brain regions/networks. Correlations between swallowing recovery and brain function changes, plus group imaging differences, will reveal tDCS's neurophysiological mechanism.
Eligibility Criteria
Inclusion Criteria: * Meet the Chinese Diagnostic Criteria for Parkinson's Disease (2016) or MDS Diagnostic Criteria for Multiple System Atrophy or Progressive Supranuclear Palsy; * VFSS examination indicates dysphagia; * Mini-Mental State Examination (MMSE) score \>23; * Willing to cooperate with the study and sign the informed consent form; Exclusion Criteria: * Comorbid with other diseases that cause dysphagia; * Comorbid with pneumonia, or severe cardiac/renal insufficiency; * Having metal implants in the body * With cognitive impairment or inability to cooperate.
Contact & Investigator
Ping Wang
PRINCIPAL INVESTIGATOR
Second Affiliated Hospital of Zhejiang University School of Medicine
Frequently Asked Questions
Who can join the NCT07153692 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Parkinson's Disease and Parkinsonism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07153692 currently recruiting?
Yes, NCT07153692 is actively recruiting participants. Contact the research team at wangping6288@zju.edu.cn for enrollment information.
Where is the NCT07153692 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT07153692 clinical trial?
NCT07153692 is sponsored by Wang Ping. The principal investigator is Ping Wang at Second Affiliated Hospital of Zhejiang University School of Medicine. The trial plans to enroll 58 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.